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Abstract 
PURPOSE: Mammographic breast and bone mineral densities (BMD) have been 
associated with luteal phase hormone concentrations in premenopausal women. We 
assessed the associations of breast and bone densities with follicular phase hormones and 
sex hormone binding globulin (SHBG) in premenopausal women given that follicular 
phase hormones have been shown to be positively associated with premenopausal breast 
cancer risk. 
METHODS: One hundred and ninety two 40-45 year old women provided a spot urine 
and/or blood sample during the follicular phase. Hormone and SHBG concentrations and 
bone density were measured and routine mammograms were accessed and digitized to 
obtain breast density measures. Regression models were fit to assess the associations 
between hormones and SHBG and breast and bone densities. 
RESULTS: Positive associations were observed between percent breast density and 
SHBG (p trend = 0.02), as well as estradiol (p trend = 0.08), after controlling for body 
mass index (BMI), number of pregnancies, and breast feeding history. In addition, a 
statistically significant inverse association was observed between total testosterone and 
head BMD (p trend = 0.01), after controlling for BMI. 
CONCLUSIONS: Associations were observed between breast and bone densities and 
serum hormone concentrations during the follicular phase of the menstrual cycle. 
 
Key words: estrogens, androgens, mammographic density, bone mineral density, 
premenopausal women 
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Introduction 
Circulating sex hormones are implicated in the etiology of certain cancers (e.g., 
breast, ovarian, and endometrial cancers) and other conditions with high morbidity in 
women (e.g., endometriosis and polycystic ovarian syndrome) arising in hormone-
sensitive tissues (1-4). Lifetime exposure to modestly increased estrogen levels could 
produce a large cumulative effect on hormone-dependent disease risk. Pike et al. for 
example, showed that a 20% increase in circulating estrogen concentrations may result in 
over a 2-fold increase in lifetime breast cancer risk (5). 
A single blood measurement may be a useful indicator of long-term hormone 
levels in premenopausal women, despite fluctuations in plasma hormone concentrations 
during the menstrual cycle. Intraclass correlation coefficients (ICCs) from a 
reproducibility study that examined plasma estrogens, androgens, and sex hormone 
binding globulin (SHBG) by phase showed that a single hormone measure provides a 
reasonable representation of hormone levels over at least three years, with ICCs ranging 
from 0.38 (follicular estradiol) to 0.83 (follicular SHBG) (6). However, there is a need for 
more evidence as to whether a single follicular phase hormone measure can be used to 
assess long-term premenopausal hormone exposure. 
One approach to determine whether lifelong hormone exposure can be 
characterized by follicular phase hormone concentrations is to assess the relationship 
between follicular phase hormone concentrations to mammographic breast and bone 
densities, which are indirect measures of lifelong hormone exposure (7-11). In a well-
characterized population of premenopausal women, we assessed the associations of 
circulating estrogen, androgen, SHBG, and urinary catechol estrogen metabolite 
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concentrations measured during the follicular phase of the menstrual cycle and high and 
low measures, respectively, of mammographic breast density and BMD. 
Materials and methods 
Recruitment 
As described in detail elsewhere (12), women were recruited from within Group 
Health (GH), a large integrated health plan in Washington State. We established 
eligibility criteria to include only premenopausal women who 1) were not currently 
taking exogenous hormones, 2) had not used hormones at all in the six months prior to 
the screening mammogram, and 3) had not used hormones for a month or more in the 6-
12 months prior to the screening mammogram. A history of hormone use in the study 
population was defined as the use of oral contraceptives, hormone patches, hormone 
injections, hormone implants, or intrauterine devices containing progesterone at any time 
prior to the 6 month-period before the screening mammogram. Women ages 40 – 45 
years who had undergone a screening mammogram in the previous 10 months were 
identified from the GH Breast Cancer Screening Program (13) and recruited based on the 
Breast Imaging Reporting and Data System (BI-RADS®) density score (14) assigned to 
their most recent screening mammogram. Our aim was to recruit approximately similar 
numbers of women with a BI-RADS® density score of 1 or 2 (combined as one group, 
where 1 = almost entirely fat and 2 = scattered fibroglandular densities), 3 
(heterogeneously dense), and 4 (extremely dense). All study procedures were approved 
by the Institutional Review Boards of the Fred Hutchinson Cancer Research Center 
(FHCRC) and GH, and all study participants provided written informed consent. 
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Mammographic breast density data 
Because studies have suggested that quantitative (i.e., digitized) measures of 
breast density create larger gradients in risk of breast cancer than do qualitative measures 
of breast density, such as BI-RADS (15), each participant’s most recent routine GH X-
ray screening mammogram prior to their study visit was digitized using a Lumysis 85 
scanner (Lumysis, Sunnyvale, CA). Films were read for percent density, dense area size, 
and total area size by a single reader using Cumulus 108, a computer-assisted 
mammogram-reading program developed at the University of Toronto (16). Briefly, the 
reader uses a sliding scale to outline the breast edge, and the dense area is identified 
based on pixel brightness. Percent density is the proportion of dense area relative to the 
total area of the breast. A random selection of 10% of the films was re-read for quality 
control purposes. The reader was blinded to the original assignment of percent density. A 
paired t-test comparing the mean percent density of the initial and repeat readings showed 
no significant difference (p = 0.81) and the initial and repeat values were highly 
correlated (Pearson correlation coefficient: 0.99, p<0.0001) with a concordance 
coefficient of 0.98. 
Each woman who undergoes screening mammography at GH completes a risk 
factor questionnaire on the day of her mammogram. From this questionnaire, we obtained 
information on the phase of menstrual cycle during which the screening mammogram 
was taken. 
 
Clinic visits and data collection 
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Prior to the appointment, self-administered health and demographics 
questionnaire, physical activity questionnaire, and food frequency questionnaire were 
mailed to each participant, who was asked to complete them and bring them to the clinic 
visit. At the clinic visit bone density, weight, height, and waist and hip circumferences 
were measured, all questionnaires were reviewed for completeness, an early morning 
blood sample (20 ml) was drawn following an overnight fast, and participants provided a 
spot urine sample. Blood and urine were transported in coolers with ice packs to the 
FHCRC Specimen Processing laboratory. Processing took place within two hours of 
collection. Blood components (i.e., serum, plasma, and buffy coats) and urine aliquots 
were stored at -70° C. An aliquot of urine was stored for creatinine analysis and the 
remaining sample was supplemented with 1 part ascorbic acid solution (100 mM ascorbic 
acid) to 30 parts urine to prevent oxidation of labile estrogen metabolites. 
 
Bone density data 
Bone mineral content (BMC) and BMD were measured at the study clinic visit 
using dual-energy X-ray densitometry [DEXA (Hologic Delphi, Hologic Inc. Bedford, 
MA)]. Bone density was measured at the anterior-posterior lumbar spine (L1-L4) and 
proximal femur, including neck and trochanteric regions. In addition, a whole body scan 
was conducted to provide information on whole body BMC and BMD, and body 
composition. All measurements were conducted as detailed in the manufacturer’s 
specifications. This included the use of a knee block for spine scans, and medial rotation 
of the femur with a foot immobilizer for the hip scans. In vitro precision of the machine 
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was monitored throughout the duration of the study in accord with established quality 
control procedures. 
 
Serum steroid hormone and SHBG concentration analyses 
The quantification of serum hormones in this study has been described in detail 
elsewhere (17). Briefly, estrone (E1), estradiol (E2), testosterone (T), androstenedione 
(A), and dehydroepiandrosterone (DHEA) were quantified by sensitive and specific 
radioimmunoassays (RIAs) (18, 19), and SHBG and DHEA sulfate were quantified by 
chemiluminescent immunoassay on the Immulite analyzer (Siemens Medical Solutions 
Diagnostics, Los Angeles, CA). Concentrations of free and bioavailable (non-SHBG-
bound) E2 and T were calculated using the measured total E2 and total T, respectively, 
and SHBG concentrations and an assumed constant for albumin (20-22). E1-sulfate (S) 
was quantified using a highly specific direct RIA (Diagnostic Systems Laboratories, 
Webster, TX). Two blinded quality control samples were included in each of five 
batches. The coefficient of variation (CV) % across all QC samples (n=10) ranged from 
6.2% for E2 to 17.2% for E1S. Mean intra-assay CVs (each CV was based on 2 QC 
samples per batch) ranged from 3.1% for SHBG to 14.9% for E1S. 
 
Urinary estrogen metabolite concentration analyses 
Measurement of urinary estrogen metabolite concentrations is described in detail 
elsewhere (17). Briefly, urinary catechol estrogen metabolite concentrations, specifically 
2-hydroxy (OH) E1 and 16α-OH E1, were measured using a commercially available 
competitive, solid-phase enzyme-linked immunoassay (ESTRAMET, ImmunaCare, 
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Corp., Bethlehem, PA). To ensure that urine samples were adequately concentrated, 
urinary creatinine concentrations were measured (12). Based on measured creatinine 
concentrations, samples were diluted 1:2 or 1:4 prior to testing with manufacturer-
supplied diluent. Estrogen metabolite concentrations were determined from a calibration 
curve derived from six standards supplied with the kit (0.625 – 15.0 ng/ml), and the ratio 
of 2-OH E1/16α-OH E1 was computed. All samples, controls, and standards were assayed 
in triplicate, and in-house and manufacturer-supplied controls were included in each of 
the assays performed. Intra-assay and inter-assay CVs for 2-OH E1 were 4.4% and 8.8%, 
respectively; for 16α-OH E1, they were 5.1% and 9.2%, respectively.  
 
Data analysis 
Measures of central tendency and categorical distributions were calculated to 
describe the characteristics of the study population. Initial evaluations of the associations 
between breast and bone densities and circulating hormone, SHBG, and urinary estrogen 
metabolite concentrations were performed using correlation analyses. Logistic regression 
models with robust standard errors were used to assess the associations of percent 
mammographic breast density and BMD and serum hormone concentrations, SHBG, and 
estrogen metabolites. We used the change-in-estimate selection method to determine the 
covariates for our models (23). For the mammographic breast density model, our 
candidate covariates were age, BMI, number of pregnancies, ethnicity, age at menarche, 
history of breast feeding, and history of hormone use based on published literature (15). 
Those variables that, when entered in the model resulted in a 10% or more change in the 
estimated exposure effect (e.g., serum E2 concentrations), included BMI, number of 
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pregnancies, and history of breast feeding. For the bone density model, our candidate 
covariates were age, BMI, age at menarche, and ethnicity (24, 25). BMI was the only 
variable that changed the estimated exposure effect (e.g., serum hormone measures) for 
BMD by 10% or more. Thus, this variable was included in our final model. BMI was a 
continuous variable, number of pregnancies was categorized (0, 1, 2+), and history of 
breast feeding was a dichotomous variable. For total E2 and total T, SHBG is one of the 
factors known to determine the amount of free and biologically active hormone and vice 
versa. As such, these variables were included in the respective models. 
Dichotomous outcome variables for breast or bone density were derived by 
categorizing subjects into the highest quartile (Q4) versus the lower three quartiles (Q1-
Q3) combined. For percent breast density, Q4 = 55.0% - 88.9% and Q1-Q3 = 0% - 
54.9%; for lumbar spine BMD, Q4 = 1.13g/cm2 – 1.34g/cm2 and Q1-Q3 = 0.73g/cm2 – 
1.12g/cm2; for head BMD, Q4 = 2.55g/cm2 – 3.34g/cm2 and Q1-Q3 = 1.57g/cm2 – 
2.54g/cm2; for pelvic BMD, Q4 = 1.24g/cm2 – 1.51g/cm2 and Q1-Q3 = 0.83g/cm2 – 
1.23g/cm2. Serum hormone, catechol estrogen metabolite, and SHBG concentrations 
were also categorized as quartiles (Q1: <25th percentile, Q2: >25th percentile - <50th 
percentile, Q3: >50th percentile - < 75th percentile, Q4: >75th percentile) and odds ratios 
for the outcome (Q4 vs. Q1-Q3 of breast or bone density) were calculated for each 
quartile of the exposure with the lowest quartile as the reference. Odds ratios and 95% 
confidence intervals are presented. We used the Cochrane-Armitage test to assess trends 
between the ordinal hormone quartile measures and bone and breast density measures. To 
assess the magnitude of difference in breast and bone densities across the quartiles of 
hormones, we calculated the median value for these measures by hormone quartile. Data 
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were analyzed using Stata/SE (version 9.0; StataCorp LP, College Station, TX), and a 
two-sided p-value of < 0.05 was considered statistically significant.  
 
Results  
Study population 
A total of 1,407 women were identified as potential participants. Of these, 367 
(26%) were ineligible, 691 (49%) refused participation, and 146 (10%) were unable to be 
interviewed or scheduled. A total of 203 women attended a study clinic visit, which was 
scheduled to occur between days 5 and 9 of the menstrual cycle; 198 (98%) actually 
attended the clinic visit between days 5 and 9 of their menstrual cycle. One hundred and 
ninety six women provided a spot urine (n = 195) and/or blood (n = 193) sample. Four 
participants had E2 levels > 400 pg/mL. Concentrations this high are considered 
periovulatory and not typical of concentrations seen between days 5 and 9 of the 
menstrual cycle; as such, we excluded these four women from our analyses. We also 
excluded one participant with a mammogram that was too dark to be analyzed for breast 
density. Therefore, a total of 191 women were included in our breast density analysis and 
192 women were included in our bone density analysis. 
The mean age of the study participants was 42.4 (SD 1.4) years and the majority 
had one or more pregnancies, had a history of hormone use, did not currently smoke, 
were white, and were highly educated (Table 1).  
Women in the highest quartile compared to the lower quartiles of breast density 
had the following characteristics: lower BMI, lower waist-to-hip ratio, lower number of 
pregnancies, older age at first birth, and absence of a history of breast-feeding (data not 
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shown). Women in the highest quartile versus the lower quartiles of bone density had the 
following characteristics: higher BMI, higher waist-to-hip ratio, and lower number of 
pregnancies (data not shown). 
Mean (SD) and median (range) values and the correlation matrices of the serum 
sex hormone concentrations, SHBG, and catechol estrogen metabolites are presented in 
Table 2. The estrogens were highly correlated, particularly E2 and free E2 (r = 0.89). The 
correlation between T and free T (r = 0.79) was also high. Thus, free E2 and free T were 
excluded from further analyses. The estrogens and catechol estrogens were moderately 
correlated (r > 0.10). The r values between the estrogens and androgens ranged from 0 
between E2 and A to 0.34 between DHEAS and E1S. Low correlations were observed 
between mammographic density and lumbar spine BMD (r = -0.11), pelvic BMD (r = -
0.29), and head BMD (r = -0.06) (data not shown). 
 
Associations between endogenous hormone, SHBG, and estrogen metabolite 
concentrations and percent mammographic breast density 
After adjusting for BMI, number of pregnancies, and history of breastfeeding, a 
borderline significant positive trend was shown between E2 and percent density [Q2 vs. 
Q1: 1.36 (95% CI: 0.43, 4.28); Q3 vs. Q1: 1.67 (95% CI: 0.57, 4.90); Q4 vs. Q1: 2.87 
(95% CI: 0.98, 8.42); p trend = 0.08; Table 3]. A statistically significant positive 
association between percent breast density and SHBG was shown [Q2 vs. Q1: OR=6.97 
(95% CI: 0.98, 49.3); Q3 vs. Q1: OR=9.84 (95% CI: 1.39, 69.8); Q4 vs. Q1: OR=11.9 
(95% CI: 1.66, 85.0); p trend = 0.02; Table 3]. In addition, a borderline significant 
positive trend was shown between 16α-OH E1 and breast density (p trend = 0.08), and a 
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significant positive association between percent density and Q3 of 2-OH E1 compared to 
Q1 [OR=4.78 (95% CI: 1.36, 16.8); Table 3] was also shown; however, the trend was not 
significant. A non-significant positive association between androstenedione and breast 
density, and a non-significant inverse association between DHEA and breast density were 
also observed (Table 3). 
 
Associations between endogenous hormone, SHBG, and estrogen metabolite 
concentrations and BMD measures 
After adjusting for BMI, no associations between circulating estrogens and any of 
our three BMD measures (lumbar spine, pelvis, head) were seen (Tables 4-6). However, 
significant and borderline significant inverse associations were shown between pelvic 
BMD and 2:16α-OH E1 and 2-OH E1 concentrations, respectively (Table 5). A significant 
inverse association between T and head BMD was observed with women in the highest 
quartile of head BMD having lower T concentration compared to women in the lower 
quartiles of head BMD [Q2 vs. Q1: OR=0.72 (95% CI: 0.31, 1.70); Q3 vs. Q1: OR=0.29 
(95% CI: 0.10, 0.80); Q4 vs. Q1: OR=0.36 (95% CI: 0.14, 0.94); p-trend = 0.01; Table 
6]. Significant inverse associations between androgens and lumbar spine BMD were also 
seen; however, the trends were not significant (Table 4). 
 
Discussion 
In this well-characterized population of healthy premenopausal women, we 
assessed the associations between breast and bone densities and follicular phase 
concentrations of estrogens and androgens, SHBG, and urinary catechol estrogen 
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metabolites. To our knowledge, this is the first study that has examined the relationships 
between concentrations of follicular phase circulating sex hormones and SHBG and 
mammographic density, and the first study to evaluate the association between catechol 
estrogen metabolites and mammographic density among premenopausal women.  
Our results showing an association of borderline significance between serum E2 
during the follicular phase and percent breast density in premenopausal women are 
consistent with previous studies that have looked at this association with estrogens during 
the luteal phase (26, 27). The positive association between percent density and E2 
observed in our study is in the hypothesized direction. 
We observed a significant positive association between percent breast density and 
SHBG. Boyd et al reported a similar positive association between mammographic breast 
density and SHBG in both pre- and postmenopausal women (26); however, SHBG only 
accounted for 10% of the variance in percent breast density among premenopausal 
women, which is much lower than 25% of the variance seen in postmenopausal women. 
This finding, in addition to an inverse association between serum free E2 concentration 
and breast density observed by Boyd et al, suggests that estrogenic effects on breast 
density are not related to the circulating free (i.e., biologically active) form of E2, and that 
SHBG may interact directly with binding sites within the breast to promote estrogenic 
effects (28). 
We also observed a significant positive association between percent breast density 
and 16α-OH E1. Our findings are similar to studies conducted in postmenopausal women 
(29). Furthermore, results from Muti et al showed an increase in breast cancer risk with 
higher concentrations of 16α-OH E1 in premenopausal women (30) suggesting that 16α-
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OH E1 may be involved in the etiology of breast cancer. Our results raise the possibility 
that the association between 16α-OH E1 and breast cancer may be mediated, in part, by 
increasing breast density. 
Estrogens are involved in bone growth by inhibiting bone resorption and 
increasing the production of hormones involved in bone development such as 1,25-
dihydroxyvitamin D, growth hormone, and insulin-like growth factor 1 (31). We 
hypothesized that higher circulating estrogens during the follicular phase would be 
positively associated with BMD. We did not observe an association between serum 
estrogen concentrations and BMD. This is consistent with previous findings in 
premenopausal women during the follicular phase (32, 33); however, significant inverse 
trends were shown between pelvic BMD and urinary 2-OH E1 and 2:16α-OH E1. This is 
consistent with a previous study in postmenopausal women that showed that women in 
the lowest quartile of 2-OH E1:16α-OH E1 were protected from bone loss over a one year 
period of follow-up, and higher urinary concentrations of 2-OH E1 was shown to be 
associated with lower BMD (34). 
We would expect higher T concentrations to be associated with higher BMD due 
to the aromatization of T into estrogens in fat and other tissues (35), and given the results 
of a previous study in estrogen-deficient premenopausal women which showed that bone 
loss (i.e., lower BMD) from the hip was significantly associated with lower androgen 
concentrations (33). In these healthy, regularly menstruating women, we observed no 
relationship between T and lumbar or pelvic BMD measures, but a significant inverse 
association between T and head BMD was observed after adjusting for BMI. Because 
head BMD is minimally influenced by muscular activity and is relatively free of 
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mechanical stress, it has been hypothesized that head BMD may provide a more accurate 
assessment of hormonal, genetic, and dietary influences on the mineral status of the 
skeleton compared to the other more frequently measured BMD sites such as the lumbar 
spine, hip, and femur (36). In this regard, our findings do not support our hypothesized 
relationship between androgens and BMD. 
There were some strengths and limitations to our study. Premenopausal women 
tend to have high breast density, so study participants were sampled based on a BI-
RADS® classification score, which allowed us to obtain a wide range of breast densities. 
However, because most women were white and well-educated, reflecting the GH 
population, and all were insured, our findings may be generalizable only to similar 
populations of women. Furthermore, bias due to the low participation rate in this study is 
possible. In the absence of any data on non-participants, bias would only be a concern if 
characteristics of non-participants that define under- or over-represented segments of the 
population are also differentially associated with the outcome in those who participate 
and those who do not. It can be argued that follicular phase hormone measures may not 
be representative of sex steroid, SHBG, and urinary catechol estrogen metabolite 
concentrations for premenopausal women throughout the menstrual cycle. Nonetheless, it 
has been shown that a reasonable characterization of interindividual differences in 
premenopausal E2 concentrations can be obtained with single blood samples taken 
between days 5 and 9 (i.e., early to mid-follicular phase of the menstrual cycle) (37). 
Further, it has been suggested that among premenopausal women, a single blood 
measurement can reliably categorize average concentrations of androgens and E1S over at 
least a 3-year period (6).  
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Another potential limitation is that a large number of statistical comparisons were 
made, suggesting that some of the statistically significant findings may have occurred by 
chance alone. Finally, the cross-sectional nature of our study cannot establish the 
temporal sequence of hormone concentrations and breast and bone density measures. 
Nevertheless, our results provide important baseline information for future research. 
In summary, in this population of premenopausal women, higher concentrations 
of estrogens and SHBG during the follicular phase of the menstrual cycle were associated 
with higher mammographic breast density. We also observed associations between 
androgens and head and lumbar spine BMD and urinary estrogen metabolite 
concentrations and pelvic BMD. Lifetime exposure to increased hormone concentrations 
is a risk factor for several hormone-dependent diseases. Our results showed some 
associations between a single hormone measure during the follicular phase of the 
menstrual cycle and biomarkers of hormone exposure, i.e., breast and bone densities. As 
such, identification of high-risk women for hormone-dependent diseases for prevention 
efforts may be possible. Further studies involving a larger sample of more diverse 
populations are needed to confirm and improve the generalizability of these findings. 
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Table 1. Characteristics of study population: Group Health, Seattle, WA – Years of recruitment 2004 
- 2005 (N = 192*) 
   
Age, y (mean, SD) 42.4 (1.4) 
   
Age at menarche, y (mean, SD) 12.8 (1.3) 
   
Age at first birth§, y (mean, SD) 29.0 (5.8) 
   
BMI, kg/m2 (mean, SD) 25.7 (4.6) 
   
Height, m (mean, SD) 1.65 (0.07) 
   
Weight, kg (mean, SD) 70.1 (13.4) 
   
Waist:Hip ratio (mean, SD) 0.79 (0.06) 
   
Parity (n, %) 
   Nulliparous 
   Had 1 or 2 children 
   Had 3+ children 
 
55 
69 
65 
 
(28.6) 
(35.9) 
(33.8) 
   
Had a history of breast-feeding§ (n, %) 111 (82.2) 
   
Had a history of hormone useŦ (n, %) 137 (71.4) 
   
First degree relative with breast and/or ovarian 
cancer (n, %) 
24 (12.5) 
   
Smoking status (n, %) 
   Current 
   Former 
   Never 
 
8 
54 
128 
 
(4.2) 
(28.1) 
(66.7) 
   
Race / ethnicity (n, %) 
   Asian 
   White 
   Other 
 
14 
166 
10 
 
(7.3) 
(86.5) 
(5.2) 
   
Years of school completed (n, %) 
   < 12 
   13 – 15 
   16 
   > 17 years 
 
12 
49 
57 
72 
 
(6.2) 
(25.5) 
(29.7) 
(37.5) 
   
Income (n, %) 
   < $49,999 
   $50,000 - $75,000 
   > $75,000 
   Prefer not to answer 
 
29 
44 
90 
26 
 
(15.1) 
(22.9) 
(46.9) 
(13.5) 
§ Among parous women only (n = 135); * Numbers may not add up to 192 for some characteristics due to missing 
values; Ŧ Use of oral contraceptives, hormone patches, hormone injections, hormone implants, or intrauterine devices 
containing progesterone at any time prior to the 6 month-period before the screening mammogram 
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Table 2. Mean (SD) and median (range) values and correlation matrices of hormone, binding protein, and urinary estrogen metabolite measures of study population 
Hormone# n Mean (SD) Median (Range) Correlation matrix 
        E1       E1S       E2         FE2        A          T        DHEA     DS        FT      SHBG     2-OH     16α-OH     2:16α- 
                                                                                                                                    E1          E1              OH E1 
Estrogens 
   E1 (pg/ml) 
   E1S (ng/ml) 
   E2 (pg/ml) 
   FE2 (pg/ml) 
 
189 
189 
189 
189 
 
74.0 
1.6 
115 
2.7 
 
(25.6) 
(0.6) 
(61.3) 
(1.5) 
 
71.0 
1.5 
97.0 
2.4 
 
(26 - 205) 
(0.5 – 5.1) 
(15 - 361) 
(0.3 – 9.2) 
 
 1.00 
 0.64     1.00 
 0.69     0.45      1.00 
 0.55     0.36      0.89     1.00 
       
Androgens 
   A (ng/ml) 
   T (ng/dl) 
   DHEA (ng/ml) 
   DS (μg/dl) 
   FT (pg/ml) 
 
189 
189 
188 
189 
189 
 
0.98 
26.6 
4.0 
89.3 
4.6 
 
(0.29) 
(9.2) 
(1.8) 
(47.8) 
(1.8) 
 
0.95 
25.4 
3.8 
78.3 
4.0 
 
(0.4 – 2.1) 
(10 – 60) 
( 0.7 – 13) 
(17 – 266) 
(1 – 12) 
 
 0.17     0.24      0           0.01   1.00 
 0.23     0.13      0.05      0.03   0.68       1.00 
 0.02     0.25     -0.08    -0.08    0.62      0.52      1.00 
-0.05     0.34     -0.17    -0.17    0.40      0.34      0.68      1.00 
 0.10     0.12     -0.14    -0.13    0.53      0.79      0.50      0.45       1.00 
                                                                                                                             
SHBG (nmol/l) 189 57.7 (24.4) 55.5 (14 – 188)  0.19     0.03      0.27      0.24    0.14      0.17      -0.01    -0.17      -0.40      1.00 
       
Urinary catechol 
estrogen metabolites 
   2-OH E1 (ng/mg cr) 
   16α-OH E1 (ng/mg cr) 
   2:16α-OH E1 
 
 
191 
191 
191 
 
 
18.7 
11.7 
1.6 
 
 
(13.0) 
(5.2) 
(0.9) 
 
 
15.0 
10.6 
1.5 
 
 
(2 – 99) 
(4 – 39) 
(0.3 – 8) 
 
 
 0.24     0.15      0.32      0.32    0.06      0.09      0.01      0            -0.01      0.17        1.00 
 0.16     0.17      0.25      0.22    0.13      0.19      0.22      0.24       0.16       0.07        0.55       1.00 
 0.13     0.04      0.17      0.18    0          -0.02     -0.15    -0.20       -0.15      0.17        0.69       -0.13           1.00 
# E1 – estrone, E1S – estrone sulfate, E2 – estradiol, A – androstenedione, T – testosterone, DHEA – dehydroepiandrosterone, DS - DHEA sulfate, SHBG – sex hormone binding globulin; F = free, OH – 
hydroxyl, cr – creatinine 
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Table 3. Adjusted§ logistic regression analysis: Percent mammographic breast density (highest quartile 
vs lower quartiles) and quartiles of serum hormones, SHBG, and urinary catechol estrogen metabolites
Hormone# (Quartile Cut points) Median 
percent 
density 
nр Odds Ratio (95% CI)η p trend 
Estrogens 
  E1 (pg/ml) 
1 (< 57) 
2 (> 57-71) 
3 (> 71-87) 
4 (> 87) 
 
 
29.5 
38.8 
30.6 
35.1 
 
 
9/39 
13/33 
11/39 
14/30 
 
 
Ref 
1.60 (0.54, 4.76) 
1.52 (0.47, 4.94) 
2.58 (0.76, 8.69) 
0.15 
  E1S (ng/ml) 
1 (< 1.14) 
2 (> 1.14-1.46) 
3 (> 1.46-1.94) 
4 (> 1.94) 
 
35.4 
29.9 
51.4 
34.0 
 
11/36 
7/39 
18/30 
11/36 
 
Ref 
0.80 (0.25, 2.52) 
2.01 (0.74, 5.43) 
0.91 (0.29, 2.80) 
0.67 
   E2 (pg/ml)† 
1 (< 68) 
2 (> 68-97) 
3 (> 97-152) 
4 (> 152) 
 
30.0 
35.5 
35.6 
41.8 
 
7/40 
10/38 
14/35 
16/28 
 
Ref 
1.36 (0.43, 4.28) 
1.67 (0.57, 4.90) 
2.87 (0.98, 8.42) 
0.08 
Androgens 
  A (ng/ml) 
1 (< 0.79) 
2 (> 0.79-0.95) 
3 (> 0.95-1.14) 
4 (> 1.14) 
 
 
26.0 
29.8 
41.1 
38.9 
 
 
12/33 
10/41 
10/35 
15/32 
 
 
Ref 
0.37 (0.12, 1.13) 
0.50 (0.17, 1.47) 
0.50 (0.17, 1.46) 
0.43 
  T (ng/dl)† 
1 (< 20.2) 
2 (> 20.2-25.4) 
3 (> 25.4-31.4) 
4 (> 31.4) 
 
37.0 
34.6 
35.9 
32.8 
 
14/33 
10/37 
13/34 
10/37 
 
Ref 
0.55 (0.17, 1.78) 
0.70 (0.24, 2.04) 
0.41 (0.13, 1.30) 
0.20 
  DHEA (ng/ml) 
1 (< 2.79) 
2 (> 2.79-3.79) 
3 (> 3.79-4.66) 
4 (> 4.66) 
 
25.5 
44.1 
39.2 
34.3 
 
8/39 
14/34 
15/31 
10/36 
 
Ref 
1.60 (0.52, 4.94) 
1.52 (0.53, 4.35) 
0.84 (0.28, 2.49) 
0.68 
  DHEA-S (μg/dl) 
1 (< 55.7) 
2 (> 55.7-78.8) 
3 (> 78.8-118) 
4 (> 118) 
 
29.8 
35.9 
35.6 
46.6 
 
9/37 
12/36 
12/36 
14/32 
 
Ref 
1.46 (0.50, 4.28) 
1.60 (0.54, 4.74) 
1.56 (0.54, 4.50) 
0.34 
Binding protein  
 SHBG (nmol/l)δ 
1 (< 40.8) 
2 (> 40.8-55.4) 
3 (> 55.4-71.3) 
4 (> 71.3) 
 
 
20.8 
30.0 
40.9 
53.7 
 
 
1/46 
9/38 
16/31 
21/26 
 
 
Ref 
6.97 (0.98, 49.3) 
9.84 (1.39, 69.8)* 
11.9 (1.66, 85.0)* 
0.02 
Urinary catechol estrogen metabolites 
  2-OH E1 (ng/mg creatinine) 
1 (< 11.0) 
2 (> 11.0-14.9) 
3 (> 14.9-22.3) 
4 (> 22.3) 
 
 
25.1 
37.0 
48.8 
40.7 
 
 
4/43 
14/34 
17/30 
12/36 
 
 
Ref 
3.31 (0.91, 12.1) 
4.78 (1.36, 16.8)* 
1.96 (0.54, 7.11) 
0.47 
  16α-OH E1 (ng/mg creatinine)    0.08 
 25
1 (< 8.13) 
2 (> 8.13-10.6) 
3 (> 10.6-14.5) 
4 (> 14.5) 
26.8 
39.6 
43.4 
39.3 
7/41 
12/35 
14/33 
14/34 
Ref 
2.14 (0.63, 7.29) 
2.15 (0.69, 6.73) 
2.89 (0.94, 8.82) 
  2:16α-OH E1 
1 (< 1.14) 
2 (> 1.14-1.49) 
3 (> 1.49-2.07) 
4 (> 2.07) 
 
23.5 
39.7 
32.2 
45.4 
 
7/40 
13/35 
9/38 
18/30 
 
Ref 
1.43 (0.44, 4.73) 
1.01 (0.27, 3.74) 
2.09 (0.63, 6.87) 
0.30 
# E1 – estrone, E1S – estrone sulfate, E2 – estradiol, A – androstenedione, T – testosterone, DHEA – 
dehydroepiandrosterone, DHEAS – DHEA sulfate, SHBG – sex hormone binding globulin, OH – hydroxy; р No. of 
women in the highest quartile of percent density / No. of women in the lower quartiles of percent density; * p < 0.05; § 
adjusted for BMI, number of pregnancies, and history of breastfeeding; † additionally adjusted for SHBG; δ additionally 
adjusted for E2 and T; η highest quartile of percent density compared to lower three quartiles of percent density 
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Table 4. Adjusted§ logistic regression analysis: Lumbar spine BMD (highest quartile vs lower 
quartiles) and quartiles of serum hormones and urinary estrogen metabolites.
Hormone# (Quartile Cut points) Median 
lumbar spine 
(g/cm2) 
nр Odds Ratio (95% CI)η p trend 
Estrogens 
  E1 (pg/ml) 
1 (< 57) 
2 (> 57-71) 
3 (> 71-87) 
4 (> 87) 
 
 
1.040 
1.058 
1.042 
1.045 
 
 
12/36 
11/37 
12/37 
13/31 
 
 
Ref 
1.02 (0.38, 2.73) 
1.00 (0.39, 2.54) 
1.30 (0.50, 3.37) 
0.64 
  E1S (ng/ml) 
1 (< 1.15) 
2 (> 1.15-1.46) 
3 (> 1.46-1.94) 
4 (> 1.94) 
 
1.058 
1.041 
1.038 
1.062 
 
15/34 
9/35 
10/38 
14/34 
 
Ref 
0.51 (0.19, 1.39) 
0.66 (0.25, 1.77) 
0.98 (0.39, 2.47) 
0.95 
   E2 (pg/ml)† 
1 (< 68) 
2 (> 68-97) 
3 (> 97-152) 
4 (> 152) 
 
1.086 
1.043 
1.039 
1.014 
 
14/36 
13/32 
7/42 
14/31 
 
Ref 
1.25 (0.50, 3.12) 
0.54 (0.20, 1.49) 
1.47 (0.57, 3.78) 
0.77 
Androgens 
  A (ng/ml) 
1 (< 0.79) 
2 (> 0.79-0.95) 
3 (> 0.95-1.15) 
4 (> 1.15) 
 
 
1.089 
1.036 
1.023 
1.055 
 
 
17/28 
7/44 
10/36 
14/33 
 
 
Ref 
0.32 (0.11, 0.95)* 
0.60 (0.22, 1.64) 
1.06 (0.40, 2.78) 
0.69 
  T (ng/dl)† 
1 (< 20.2) 
2 (> 20.2-25.4) 
3 (> 25.4-31.5) 
4 (> 31.5) 
 
1.089 
1.026 
1.038 
1.014 
 
18/29 
9/39 
9/38 
12/35 
 
Ref 
0.40 (0.15, 1.05) 
0.44 (0.17, 1.19) 
0.61 (0.25, 1.48) 
0.32 
  DHEA (ng/ml) 
1 (< 2.82) 
2 (> 2.82-3.79) 
3 (> 3.79-4.71) 
4 (> 4.71) 
 
1.085 
1.045 
1.009 
1.069 
 
15/32 
12/36 
5/41 
15/32 
 
Reference 
0.79 (0.30, 2.06) 
0.31 (0.10, 0.99)* 
1.21 (0.48, 3.03) 
0.98 
  DHEA-S (μg/dL) 
1 (< 55.7) 
2 (> 55.7-78.3) 
3 (> 78.3-118) 
4 (> 118) 
 
1.062 
1.033 
1.039 
1.039 
 
12/34 
14/34 
9/40 
13/33 
 
Ref 
1.24 (0.46, 3.30) 
0.57 (0.21, 1.58) 
1.27 (0.48, 3.36) 
0.97 
Binding protein  
 SHBG (nmol/l)δ 
1 (< 41.1) 
2 (> 41.1-55.5) 
3 (> 55.5-71.2) 
4 (> 71.2) 
 
 
1.090 
1.019 
1.040 
1.021 
 
 
16/32 
12/35 
12/35 
8/39 
 
 
Ref 
1.14 (0.44, 3.00) 
1.33 (0.45, 3.92) 
0.93 (0.28, 3.09) 
0.96 
Urinary catechol estrogen metabolites 
  2-OH E1 (ng/mg creatinine) 
1 (< 11.0) 
2 (> 11.0-15.0) 
3 (> 15.0-22.3) 
4 (> 22.3) 
 
 
1.064 
1.069 
1.018 
1.042 
 
 
15/32 
14/35 
8/39 
10/38 
 
 
Ref 
0.97 (0.39, 2.41) 
0.53 (0.19, 1.48) 
0.74 (0.28, 2.00) 
0.36 
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  16α-OH E1 (ng/mg creatinine) 
1 (< 8.13) 
2 (> 8.13-10.6) 
3 (> 10.6-14.5) 
4 (> 14.5) 
 
1.066 
1.062 
1.036 
1.026 
 
15/33 
13/34 
9/39 
10/38 
 
Ref 
0.90 (0.36, 2.25) 
0.55 (0.21, 1.46) 
0.64 (0.24, 1.70) 
0.25 
  2:16α-OH E1 
1 (< 1.14) 
2 (> 1.14-1.49) 
3 (> 1.49-2.07) 
4 (> 2.07) 
 
1.061 
1.069 
1.037 
1.035 
 
13/34 
15/34 
9/38 
10/38 
 
Ref 
1.41 (0.56, 3.52) 
0.70 (0.26, 1.89) 
0.98 (0.37, 2.60) 
0.60 
# E1 – estrone, E1S – estrone sulfate, E2 – estradiol, A – androstenedione, T – testosterone, DHEA – 
dehydroepiandrosterone, DHEAS – DHEA sulfate, SHBG – sex hormone binding globulin, OH – hydroxy; р No. of 
women in the highest quartile of BMD / No. of women in the lower quartiles of BMD; * p < 0.05; § adjusted for BMI; 
† additionally adjusted for SHBG; δ additionally adjusted for E2 and T; η highest quartile of BMD compared to lower 
three quartiles of BMD 
 
 28
 
Table 5. Adjusted§ logistic regression analysis: Pelvic BMD (highest quartile vs lower quartiles) and 
quartiles of serum hormones and urinary estrogen metabolites.
Hormone# (Quartile Cut points) Median 
pelvic BMD 
(g/cm2) 
nр Odds Ratio (95% CI)η p trend 
Estrogens 
  E1 (pg/ml) 
1 (< 57) 
2 (> 57-71) 
3 (> 71-87) 
4 (> 87) 
 
 
1.168 
1.138 
1.145 
1.141 
 
 
16/32 
7/41 
13/36 
12/32 
 
 
Ref 
0.38 (0.13, 1.12) 
0.71 (0.28, 1.79) 
0.72 (0.26, 2.03) 
0.73 
  E1S (ng/ml) 
1 (< 1.15) 
2 (> 1.15-1.46) 
3 (> 1.46-1.94) 
4 (> 1.94) 
 
1.138 
1.158 
1.147 
1.130 
 
12/37 
14/30 
9/39 
13/35 
 
Ref 
1.31 (0.46, 3.72) 
0.89 (0.30, 2.63) 
1.29 (0.47, 3.57) 
0.81 
   E2 (pg/ml)† 
1 (< 68) 
2 (> 68-97) 
3 (> 97-152) 
4 (> 152) 
 
1.189 
1.156 
1.136 
1.134 
 
18/32 
11/34 
5/44 
14/31 
 
Ref 
0.80 (0.30, 2.14) 
0.30 (0.09, 1.00) 
1.45 (0.54, 3.89) 
0.85 
Androgens 
  A (ng/ml) 
1 (< 0.79) 
2 (> 0.79-0.95) 
3 (> 0.95-1.15) 
4 (> 1.15) 
 
 
1.198 
1.141 
1.139 
1.130 
 
 
18/27 
9/42 
9/37 
12/35 
 
 
Reference 
0.46 (0.15, 1.40) 
0.58 (0.20, 1.66) 
1.07 (0.38, 2.98) 
0.83 
  T (ng/dl)† 
1 (< 20.2) 
2 (> 20.2-25.4) 
3 (> 25.4-31.5) 
4 (> 31.5) 
 
1.152 
1.145 
1.138 
1.133 
 
14/33 
11/37 
10/37 
13/34 
 
Reference 
0.84 (0.30, 2.37) 
0.98 (0.34, 2.86) 
1.42 (0.52, 3.90) 
0.46 
  DHEA (ng/ml) 
1 (< 2.82) 
2 (> 2.82-3.79) 
3 (> 3.79-4.71) 
4 (> 4.71) 
 
1.162 
1.137 
1.114 
1.161 
 
14/33 
9/39 
9/37 
15/32 
 
Reference 
0.62 (0.21, 1.84) 
0.84 (0.26, 2.73) 
1.67 (0.61, 4.57) 
0.27 
  DHEA-S (μg/dL) 
1 (< 55.7) 
2 (> 55.7-78.3) 
3 (> 78.3-118) 
4 (> 118) 
 
1.166 
1.129 
1.138 
1.144 
 
11/35 
14/34 
9/40 
14/32 
 
Reference 
1.53 (0.52, 4.53) 
0.55 (0.18, 1.65) 
1.89 (0.67, 5.35) 
0.58 
Binding protein  
 SHBG (nmol/l)δ 
1 (< 41.1) 
2 (> 41.1-55.5) 
3 (> 55.5-71.2) 
4 (> 71.2) 
 
 
1.217 
1.162 
1.136 
1.119 
 
 
23/25 
11/36 
7/40 
7/40 
 
 
Reference 
0.62 (0.24, 1.61) 
0.40 (0.12, 1.31) 
0.50 (0.15, 1.71) 
0.22 
Urinary catechol estrogen metabolites 
  2-OH E1 (ng/mg creatinine) 
1 (< 11.0) 
2 (> 11.0-15.0) 
3 (> 15.0-22.3) 
4 (> 22.3) 
 
 
1.170 
1.142 
1.133 
1.125 
 
 
16/31 
17/32 
8/39 
6/42 
 
 
Ref 
1.37 (0.53, 3.55) 
0.55 (0.18, 1.64) 
0.43 (0.14, 1.37) 
0.06 
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  16α-OH E1 (ng/mg creatinine) 
1 (< 8.13) 
2 (> 8.13-10.6) 
3 (> 10.6-14.5) 
4 (> 14.5) 
 
1.144 
1.163 
1.132 
1.137 
 
15/33 
10/37 
10/38 
12/36 
 
Ref 
0.64 (0.23, 1.77) 
0.64 (0.23, 1.77) 
0.90 (0.32, 2.53) 
0.84 
  2:16α-OH E1 
1 (< 1.14) 
2 (> 1.14-1.49) 
3 (> 1.49-2.07) 
4 (> 2.07) 
 
1.179 
1.152 
1.141 
1.116 
 
19/28 
14/35 
7/40 
7/41 
 
Ref 
0.76 (0.30, 1.95) 
0.27 (0.09, 0.84)* 
0.41 (0.14, 1.16) 
0.03 
# E1 – estrone, E1S – estrone sulfate, E2 – estradiol, A – androstenedione, T – testosterone, DHEA – 
dehydroepiandrosterone, DHEAS – DHEA sulfate, SHBG – sex hormone binding globulin, OH – hydroxy; р No. of 
women in the highest quartile of BMD / No. of women in the lower quartiles of BMD; * p < 0.05; § adjusted for BMI; 
† additionally adjusted for SHBG; δ additionally adjusted for E2 and T; η highest quartile of BMD compared to lower 
three quartiles of BMD 
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Table 6. Adjusted§ logistic regression analysis: Head BMD (highest quartile vs lower quartiles) and 
quartiles of serum hormones and urinary estrogen metabolites.
Hormone# (Quartile Cut points) Median 
head BMD 
(g/cm2) 
nр Odds Ratio (95% CI)η p trend 
Estrogens 
  E1 (pg/ml) 
1 (< 57) 
2 (> 57-71) 
3 (> 71-87) 
4 (> 87) 
 
 
2.299 
2.305 
2.332 
2.409 
 
 
14/34 
11/37 
11/38 
12/32 
 
 
Ref 
0.75 (0.30, 1.87) 
0.71 (0.28, 1.77) 
0.92 (0.37, 2.27) 
0.81 
  E1S (ng/ml) 
1 (< 1.15) 
2 (> 1.15-1.46) 
3 (> 1.46-1.94) 
4 (> 1.94) 
 
2.320 
2.348 
2.239 
2.390 
 
12/37 
13/31 
13/35 
10/38 
 
Ref 
1.26 (0.50, 3.17) 
1.18 (0.47, 2.96) 
0.82 (0.32, 2.15) 
0.69 
   E2 (pg/ml)† 
1 (< 68) 
2 (> 68-97) 
3 (> 97-152) 
4 (> 152) 
 
2.350 
2.282 
2.386 
2.308 
 
12/38 
12/33 
12/37 
12/33 
 
Ref 
1.27 (0.50, 3.23) 
1.26 (0.50, 3.18) 
1.42 (0.54, 3.72) 
0.50 
Androgens 
  A (ng/ml) 
1 (< 0.79) 
2 (> 0.79-0.95) 
3 (> 0.95-1.15) 
4 (> 1.15) 
 
 
2.403 
2.269 
2.263 
2.346 
 
 
16/29 
12/39 
10/36 
10/37 
 
 
Reference 
0.58 (0.23, 1.44) 
0.52 (0.20, 1.37) 
0.52 (0.20, 1.35)  
0.19 
  T (ng/dl)† 
1 (< 20.2) 
2 (> 20.2-25.4) 
3 (> 25.4-31.5) 
4 (> 31.5) 
 
2.450 
2.305 
2.237 
2.295 
 
18/29 
15/33 
7/40 
8/39 
 
Reference 
0.72 (0.31, 1.70) 
0.29 (0.10, 0.80)* 
0.36 (0.14, 0.94)* 
0.01 
  DHEA (ng/ml) 
1 (< 2.82) 
2 (> 2.82-3.79) 
3 (> 3.79-4.71) 
4 (> 4.71) 
 
2.355 
2.284 
2.286 
2.320 
 
13/34 
15/33 
11/35 
8/39 
 
Reference 
1.24 (0.51, 3.02) 
0.88 (0.34, 2.27) 
0.56 (0.21, 1.53) 
0.19 
  DHEA-S (μg/dL) 
1 (< 55.7) 
2 (> 55.7-78.3) 
3 (> 78.3-118) 
4 (> 118) 
 
2.343 
2.385 
2.356 
2.226 
 
13/33 
13/35 
14/35 
8/38 
 
Reference 
0.95 (0.38, 2.37) 
1.00 (0.41, 2.44) 
0.55 (0.20, 1.49) 
0.29 
Binding protein  
 SHBG (nmol/l)δ 
1 (< 41.1) 
2 (> 41.1-55.5) 
3 (> 55.5-71.2) 
4 (> 71.2) 
 
 
2.394 
2.356 
2.302 
2.282 
 
 
14/34 
14/33 
14/33 
6/41 
 
 
Reference 
1.22 (0.47, 3.15) 
1.23 (0.44, 3.47) 
0.46 (0.13, 1.63) 
0.22 
Urinary catechol estrogen metabolites 
  2-OH E1 (ng/mg creatinine) 
1 (< 11.0) 
2 (> 11.0-15.0) 
3 (> 15.0-22.3) 
4 (> 22.3) 
 
 
2.403 
2.282 
2.302 
2.272 
 
 
12/35 
12/37 
13/34 
11/37 
 
 
Ref 
1.00 (0.39, 2.54) 
1.21 (0.48, 3.08) 
0.97 (0.36, 2.57) 
0.94 
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  16α-OH E1 (ng/mg creatinine) 
1 (< 8.13) 
2 (> 8.13-10.6) 
3 (> 10.6-14.5) 
4 (> 14.5) 
 
2.365 
2.295 
2.320 
2.265 
 
12/36 
13/34 
11/37 
12/36 
 
Ref 
1.18 (0.47, 2.93) 
0.93 (0.37, 2.35) 
1.04 (0.42, 2.60) 
0.94 
  2:16α-OH E1 
1 (< 1.14) 
2 (> 1.14-1.49) 
3 (> 1.49-2.07) 
4 (> 2.07) 
 
2.364 
2.386 
2.276 
2.281 
 
12/35 
12/37 
12/35 
12/36 
 
Ref 
1.01 (0.39, 2.62) 
1.05 (0.41, 2.70) 
1.10 (0.41, 2.93) 
0.83 
# E1 – estrone, E1S – estrone sulfate, E2 – estradiol, A – androstenedione, T – testosterone, DHEA – 
dehydroepiandrosterone, DHEAS – DHEA sulfate, SHBG – sex hormone binding globulin, OH – hydroxy; р No. of 
women in the highest quartile of BMD / No. of women in the lower quartiles of BMD; * p < 0.05; § adjusted for BMI; † 
additionally adjusted for SHBG; δ additionally adjusted for E2 and T; η highest quartile of BMD compared to lower three 
quartiles of BMD 
 
